Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study

Supplemental Digital Content is available in the text.

[1]  Hyunyoung Jeong,et al.  Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites , 2018, Drug Metabolism and Disposition.

[2]  H. Sokol,et al.  Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic , 2017, Front. Microbiol..

[3]  Nora C. Toussaint,et al.  Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation , 2015, PloS one.

[4]  S. Kim,et al.  Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. , 2014, Kidney international.

[5]  G. Koren,et al.  Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  W. Weimar,et al.  High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Teuteberg,et al.  Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. , 2010, Transplantation proceedings.

[8]  S. Federico,et al.  Pharmacokinetic Interaction between Levofloxacin and Ciclosporin or Tacrolimus in Kidney Transplant Recipients , 2006, Clinical pharmacokinetics.

[9]  J. Borrás-Blasco,et al.  Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia. , 2005, The American journal of the medical sciences.

[10]  P. Rutgeerts,et al.  Cytochrome P450 3A4 and P‐glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  R. Yamazaki,et al.  Tacrolimus–azithromycin interaction in a recipient of allogeneic bone marrow transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[13]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[14]  S. McCann,et al.  Evaluation of a rapid micro-scale assay for tacrolimus by liquid chromatography-tandem mass spectrometry , 2002, Annals of clinical biochemistry.

[15]  D. Fish,et al.  Possible Interaction Between Intravenous Azithromycin and Oral Cyclosporine , 2001, Pharmacotherapy.

[16]  D. Urbauer,et al.  Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. , 2000, Journal of the American Society of Nephrology : JASN.

[17]  D. Urbauer,et al.  Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. , 1996, Transplantation.

[18]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.